Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

2025 sees the National Advertising Division (NAD), the Children’s Advertising Review Unit (CARU), and the Federal Trade Commission (FTC) uniting for the most assertive oversight yet of hemp-CBD and THC advertising. As novel product types—especially fast-acting, nano, and microdose cannabinoid offerings—gain traction, regulators are raising the bar on evidence, disclosure, and child-protection requirements in marketing.
The National Advertising Division (NAD), under the BBB National Programs, is the primary U.S. advertising industry self-regulatory body. Historically, its focus has been on consumer goods—but 2025 marks a notable expansion into closely scrutinizing claims in emerging wellness verticals, especially those containing cannabinoids like CBD and THC.
While the NAD can’t fine companies or force compliance, its decisions carry real weight, often triggering FTC investigations or leading to public compliance failures that can damage brand reputations. When claims are found unsupported, NAD refers cases to the FTC or FDA, as seen in recent more aggressive referral patterns (see recent NAD decision summaries).
CBD and THC brands increasingly tout “fast absorption,” “nano-delivery,” or “microdose mood support.” In 2025, NAD/CARU are scrutinizing:
Only "competent and reliable scientific evidence"—ideally gold-standard clinical trials matching the exact product type and dose—will suffice (FTC guidance). Marketers can expect swift NAD challenges if claims outpace published science, especially as nano and microdose formats proliferate.
CARU (Children’s Advertising Review Unit) and the FTC have prioritized:
States often require age-gating and robust age verification for sales, but in 2025, even products lawfully restricted to adults are being flagged for unintentional youth appeal (see compliance discussion). Brands must err on the side of caution in creative development and consider how a regulator or competitor might perceive the total marketing mix.
Social influencers, customer reviews, and testimonials are now central to cannabinoid campaigns. Under the updated FTC Endorsement Guides (2024-2025):
NAD is increasingly referring influencer-related cases to the FTC, especially when performance claims breach substantiation requirements or fail to include appropriate disclosures.
The NAD’s self-regulatory process is not just advisory. When an advertiser fails to comply, the NAD refers the case to the [FTC] or FDA, as occurred in high-profile decisions against supplement and beverage companies this year. This is especially true for:
Once at the FTC, brands may face:
Per FTC and NAD direction, health-related claims (e.g., relief, “feel it fast,” sleep, mood, anti-hangover effects) must be:
For novel delivery methods (fast-acting, nano, microdose), animal studies, unrelated product references, or in vitro research are not sufficient. Brands must develop or source contemporary human data or modify claims to reflect what is actually proven.
Even if your product is restricted to those 21+, regulators may challenge:
Regulators look at the total impression your marketing creates—not only actual sales to kids. For multi-state and online businesses, the safest course is to avoid childlike visual cues altogether.
The new FTC Endorsement Guides clarify:
If the NAD or FTC finds influencers overstating product benefits, omitting paid relationships, or creating kid-appealing content, brands will be held accountable, regardless of age-targeting or intent.
To protect your business as NAD, CARU, and the FTC ramp up enforcement against cannabinoid products in late 2025, follow this pre-campaign review checklist:
Stay proactive: Set up substantiation files, vet claims, and monitor all creative and promotional partners—don’t wait for a regulator or competitor challenge to expose gaps.
Let CannabisRegulations.ai support your Q4 campaign audits and substantiation strategy. Stay compliant, avoid reputational and enforcement risks, and unlock new opportunities with real-time regulatory intelligence.